Search
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalIt possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. … Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding.
Products: MEDSAMIC SOLUTION FOR INJECTION 100MG/ML, MEDSAMIC 100MG/ML SOLUTION FOR INJECTIONPalopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA. … Palopegteriparatide is a prodrug consisting of PTH(1-34) conjugated to a methoxy polyethylene glycol carrier (mPEG) via a proprietary TransCon Linker.
Synonyms: oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole, Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34Liraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. … Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.
Synonyms: N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptideProducts: solution for injection in pre-filled pen 6mg/ml, SOLUTION FOR INJECTION IN PRE-FILLED PEN 6MG/MLColfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawnColfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome.
Acrizanib
go.drugbank.com/drugs/DB16081InvestigationalAcrizanib is under investigation in clinical trial NCT02355028 (LHA510 Proof-of-concept Study as a Maintenance Therapy for Patients With Wet Age-related Macular Degeneration).
Categories: Compounds used in a research, industrial, or household settingNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria
Vasomera
go.drugbank.com/drugs/DB16498InvestigationalCategories: Experimental Unapproved Treatments for COVID-19LJP 1082
go.drugbank.com/drugs/DB05446ExperimentalLJP 1082 is undergoing trial for for the treatment of stroke, deep-vein thrombosis and other conditions associated with antibody-mediated thrombosis. … The target of the LJP 1082's clot-promoting antibodies is a small region on a key blood protein called beta 2-glycoprotein I.
Categories: Compounds used in a research, industrial, or household settingGalidesivir
go.drugbank.com/drugs/DB11676Investigational[L12042] Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19. … Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus.
Categories: Experimental Unapproved Treatments for COVID-19Synonyms: Immucillin A, Immucillin-A